AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Amiloride-sensitive amine oxidase [copper-containing]

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P19801

UPID:

AOC1_HUMAN

Alternative names:

Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; Histaminase; Kidney amine oxidase

Alternative UPACC:

P19801; C9J690; Q16683; Q16684; Q56II4; Q6GU42

Background:

Amiloride-sensitive amine oxidase [copper-containing], also known as Amiloride-binding protein 1, Amine oxidase copper domain-containing protein 1, Histaminase, and Kidney amine oxidase, plays a crucial role in the degradation of biogenic amines such as putrescine, histamine, spermine, and spermidine. These compounds are pivotal in various physiological processes including allergic and immune responses, cell proliferation, tissue differentiation, tumor formation, and apoptosis.

Therapeutic significance:

Understanding the role of Amiloride-sensitive amine oxidase [copper-containing] could open doors to potential therapeutic strategies. Its involvement in the regulation of compounds critical to immune responses and cell proliferation highlights its potential as a target in treating diseases related to immune system dysregulation and cancer.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.